1. Home
  2. Detail

@infinitezeo: ANXIETY STOP! 🛑 😭 #anxienty #insideout #tiktok

Zeo Batten
Zeo Batten
Open In TikTok:
Region: US
Wednesday 29 April 2026 01:43:16 GMT
961
45
0
3

Music

Download

No Watermark .mp4 (2.18MB) No Watermark(HD) .mp4 (2.18MB) Watermark .mp4 (0MB) Music .mp3

Comments

There are no more comments for this video.
To see more videos from user @infinitezeo, please go to the Tikwm homepage.

Other Videos

@Rafael Cabral @Viroubalaio o que deixa esse projeto ainda mais legal e a humildade desses caras #rafaelcabralcy #mjmusiccy #sucesso
@Rafael Cabral @Viroubalaio o que deixa esse projeto ainda mais legal e a humildade desses caras #rafaelcabralcy #mjmusiccy #sucesso
Welcome to Her Divine Destiny a space for single Christian women who desire to date with discernment, heal and grow. If you’re in a season of healing, growing, or trusting God with your love story, comment “MY DESTINY” below and follow this page. Your journey has purpose, and you belong here.
Welcome to Her Divine Destiny a space for single Christian women who desire to date with discernment, heal and grow. If you’re in a season of healing, growing, or trusting God with your love story, comment “MY DESTINY” below and follow this page. Your journey has purpose, and you belong here.
#policebodycam #truecrimeclips #caughtoncamera #policearrest #viralbodycam 🔥
#policebodycam #truecrimeclips #caughtoncamera #policearrest #viralbodycam 🔥
#police #cops #bodycam #fyp
#police #cops #bodycam #fyp
It’s all love ❤️ 👏🏾 #gehgeh
It’s all love ❤️ 👏🏾 #gehgeh
Emily Pearson, who lives in Minneapolis, has spent most of her life unable to tolerate sunlight. Her symptoms began at 8, when minutes outdoors could leave her hands and feet in severe pain for days. At 17, doctors at the Mayo Clinic in Rochester, Minnesota, diagnosed her with erythropoietic protoporphyria (EPP), a rare disorder that causes painful reactions to sunlight. In 2025, Pearson learned about a clinical trial for bitopertin, a drug that targets protoporphyrin IX, a molecule activated by sunlight in people with EPP. She began taking the drug in July 2025 and, within weeks, her tolerance to sunlight began to increase. Bitopertin is now in Phase 3 trials, with 183 patients enrolled and data expected later this year. The FDA has declined to review the drug for expedited approval, saying more data is needed on its impact.
Emily Pearson, who lives in Minneapolis, has spent most of her life unable to tolerate sunlight. Her symptoms began at 8, when minutes outdoors could leave her hands and feet in severe pain for days. At 17, doctors at the Mayo Clinic in Rochester, Minnesota, diagnosed her with erythropoietic protoporphyria (EPP), a rare disorder that causes painful reactions to sunlight. In 2025, Pearson learned about a clinical trial for bitopertin, a drug that targets protoporphyrin IX, a molecule activated by sunlight in people with EPP. She began taking the drug in July 2025 and, within weeks, her tolerance to sunlight began to increase. Bitopertin is now in Phase 3 trials, with 183 patients enrolled and data expected later this year. The FDA has declined to review the drug for expedited approval, saying more data is needed on its impact.

About

Legal